Antisense Pharma is a biopharmaceutical company committed to research and development of innovative medicines. Our drugs enable targeted treatment of aggressive tumor diseases. Our main objective is to extend the life expectancy of patients considerably and, at the same time, to improve their quality of life. 

Founded in 1998, the company is located at the BioPark in Regensburg – one of the most successful biotechnology centers in Germany. Our executive management has many years of entrepreneurial experience, expertise in the biopharmaceutical sector and a sound medical and scientific background. It is supported by a dedicated team with broad experience in the development, approval and marketing of new medicines. 

Our lead product, currently in development belongs to the ‘targeted therapies’, i.e. it blocks the synthesis of key proteins, which are responsible for the onset and progression of especially aggressive tumor diseases. This drug does not alter the genome. With this novel approach, we treat the cause of the disease and not merely its symptoms. 

Trabedersen, is our most advanced drug in terms of clinical development. We are currently in preparation of a randomized and active controlled Phase II study of 2^nd line monotherapy of metastatic pancreatic cancer patients.

We are also planning to evaluate trabedersen in combination with standard therapy as 1^st line therapy in GBM and metastatic pancreatic cancer patients.

Antisense Pharma is an international leader in the development of antisense drugs.